David M Nagorney
Overview
Explore the profile of David M Nagorney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
7573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gudmundsdottir H, Graham R, Greipp P, Habermann E, Knudson R, Brandt C, et al.
J Neuroendocrinol
. 2025 Feb;
:e70003.
PMID: 39945220
Given the heterogeneous clinical behavior of pancreatic neuroendocrine tumors (pNETs), improved prognostic markers are needed to guide management and post-resection surveillance. Patients who underwent resection of large (≥3 cm) sporadic...
2.
Surgical and oncologic outcomes for liver resections of cystic neuroendocrine tumor liver metastasis
Ammann M, Adjei Antwi S, Gudmundsdottir H, Hackl H, Santol J, Guillot B, et al.
Eur J Surg Oncol
. 2024 Nov;
51(1):109464.
PMID: 39580261
Background: Cystic neuroendocrine tumor liver metastases (NETLM) are rare and dynamics in the liquid compartment often misinterpreted as rapid progression, affecting selection for liver resection candidates. This study retrospectively evaluates...
3.
De La Fuente J, Lui J, Lennon R, Chatterjee A, Graham R, Zhang L, et al.
Gastro Hep Adv
. 2024 Aug;
1(6):1099-1107.
PMID: 39131265
Background And Aims: Management of intraductal papillary mucinous neoplasms (IPMNs) relies on clinical and imaging features to select patients for either pancreatectomy or periodic image-based surveillance. We aimed to compare...
4.
Ammann M, Gudmundsdottir H, Hackl H, Adjei Antwi S, Santol J, Habermann E, et al.
Ann Surg Oncol
. 2024 May;
31(8):4931-4941.
PMID: 38717544
Background: Surgical cytoreduction for neuroendocrine tumor liver metastasis (NETLM) consistently shows positive long-term outcomes. Despite reservations in guidelines for surgery when the primary tumor is unidentified (UP-NET), this study compared...
5.
Gudmundsdottir H, Fogliati A, Grotz T, Thiels C, Warner S, Smoot R, et al.
Ann Surg Oncol
. 2024 Apr;
31(8):5370-5376.
PMID: 38689169
Background: Cytoreductive hepatectomy can improve survival and symptoms of hormonal excess in patients with small intestinal neuroendocrine tumor (siNET) liver metastases, but whether to proceed when peritoneal metastases are encountered...
6.
Ammann M, Kinney M, Gudmundsdottir H, Santol J, Thiels C, Warner S, et al.
Ann Surg Oncol
. 2024 Apr;
31(6):3976-3977.
PMID: 38619707
No abstract available.
7.
8.
Fiorentini G, Zironda A, Calini G, Abdalla S, Nagorney D, Warner S, et al.
HPB (Oxford)
. 2023 Aug;
25(11):1337-1344.
PMID: 37626006
Background: Open combined resections of colorectal primary tumors and synchronous liver metastases have become common in selected cases. However, evidences favoring a minimally invasive (MIS) approach are still limited. The...
9.
Gudmundsdottir H, Habermann E, Vierkant R, Starlinger P, Thiels C, Warner S, et al.
Ann Surg Oncol
. 2023 May;
30(8):4840-4851.
PMID: 37208566
Background: Distant metastases are the strongest predictor of poor prognosis for patients with neuroendocrine tumors (NETs). Cytoreductive hepatectomy (CRH) can relieve symptoms of hormonal excess and prolong survival for patients...
10.
Gudmundsdottir H, Yonkus J, Alva-Ruiz R, Kendrick M, Smoot R, Warner S, et al.
J Am Coll Surg
. 2023 Apr;
237(1):49-57.
PMID: 37026837
Background: Accurate staging prior to resection of pancreatic ductal adenocarcinoma (PDAC) is imperative to avoid unnecessary operative morbidity and oncologic futility in patients with occult intra-abdominal distant metastases. We aimed...